Tishcon Corp. Receives Orphan Drug Designations for Coenzyme Q10 in the Treatment of Pediatric Congestive Heart Failure and Huntington's Disease


Home

TISHCON CORP. (April 16, 2004 - Westbury, NY) announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of :
 1- Pediatric Congestive Heart Failure, and
 2- Huntington's Disease

Tishcon Corp. was also granted an Orphan Drug Designation for Coenzyme Q10 (Ubi-Q-Gel®) in the treatment of Mitochondrial Cytopathies, in 1999.

Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software

This article has been moved here